X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-06 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $120.03 | -8,396 | 29,521 | -22% | -$1,007,780 | |||||
| D | 2023-12-06 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $119.86 | -20,830 | 35,882 | -37% | -$2,496,648 | |||||
| D | 2023-12-01 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $116.77 | -5,000 | 203,697 | -2% | -$583,837 | |||||
2023-11-29 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $113.57 | -2,331 | 11,732 | -17% | -$264,733 | ||||||
2023-11-27 | NBIX | Lippoldt Darin | GC | S - Sale | $112.27 | -10,919 | 35,882 | -23% | -$1,225,911 | ||||||
2023-10-02 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $112.68 | -1,437 | 4,894 | -23% | -$161,921 | ||||||
| D | 2023-09-12 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $115.02 | -5,000 | 203,697 | -2% | -$575,120 | |||||
| D | 2023-09-01 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $110.06 | -5,000 | 203,697 | -2% | -$550,316 | |||||
2023-09-01 | NBIX | Cooke Julie | CHRO | S - Sale | $110.93 | -824 | 17,263 | -5% | -$91,406 | ||||||
2023-08-30 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $107.60 | -2,733 | 3,460 | -44% | -$294,058 | ||||||
2023-08-28 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale | $107.52 | -1,431 | 5,931 | -19% | -$153,861 | ||||||
2023-08-21 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $107.38 | -3,198 | 29,521 | -10% | -$343,388 | ||||||
2023-08-21 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $107.37 | -3,198 | 9,638 | -25% | -$343,368 | ||||||
2023-08-21 | NBIX | Lippoldt Darin | GC | S - Sale | $107.39 | -2,132 | 46,991 | -4% | -$228,951 | ||||||
2023-08-21 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $107.40 | -9,328 | 499,754 | -2% | -$1,001,816 | ||||||
2023-08-21 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $107.41 | -2,132 | 130,250 | -2% | -$228,993 | ||||||
2023-08-21 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale | $107.42 | -1,404 | 4,645 | -23% | -$150,820 | ||||||
2023-08-21 | NBIX | Cooke Julie | CHRO | S - Sale | $107.41 | -2,132 | 18,087 | -11% | -$228,991 | ||||||
2023-08-21 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $107.41 | -1,600 | 6,193 | -21% | -$171,862 | ||||||
2023-08-21 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $107.40 | -1,600 | 36,436 | -4% | -$171,836 | ||||||
2023-08-21 | NBIX | Abernethy Matt | CFO | S - Sale | $107.39 | -2,132 | 27,131 | -7% | -$228,958 | ||||||
| D | 2023-05-01 | NBIX | Rastetter William H | Dir | S - Sale+OE | $101.43 | -4,300 | 42,785 | -9% | -$436,135 | |||||
2023-05-01 | NBIX | Cooke Julie | CHRO | S - Sale | $103.89 | -11,397 | 16,169 | -41% | -$1,184,049 | ||||||
2023-04-25 | NBIX | Cooke Julie | CHRO | S - Sale | $103.82 | -100 | 27,561 | 0% | -$10,382 | ||||||
2023-04-24 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $103.48 | -14,400 | 26,644 | -35% | -$1,490,059 | ||||||
| DM | 2023-04-19 | NBIX | Rastetter William H | Dir | S - Sale+OE | $105.03 | -6,937 | 39,460 | -15% | -$728,605 | |||||
| M | 2023-02-06 | NBIX | Cooke Julie | CHRO | S - Sale | $102.77 | -17,079 | 27,424 | -38% | -$1,755,121 | |||||
| M | 2023-02-06 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $102.74 | -16,525 | 41,015 | -29% | -$1,697,707 | |||||
2023-02-07 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $102.30 | -4,508 | 6,525 | -41% | -$461,166 | ||||||
| M | 2023-02-06 | NBIX | Lloyd-Smith Malcolm | Chief Integration Officer | S - Sale | $102.64 | -15,318 | 42,337 | -27% | -$1,572,197 | |||||
| M | 2023-02-06 | NBIX | Lippoldt Darin | GC | S - Sale | $102.71 | -16,275 | 44,973 | -27% | -$1,671,637 | |||||
| M | 2023-02-06 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $102.90 | -29,044 | 491,365 | -6% | -$2,988,758 | |||||
| M | 2023-02-06 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $102.80 | -17,004 | 128,096 | -12% | -$1,747,920 | |||||
| M | 2023-02-06 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $102.49 | -25,238 | 4,755 | -84% | -$2,586,741 | |||||
| M | 2023-02-06 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $102.70 | -19,650 | 34,381 | -36% | -$2,018,105 | |||||
| M | 2023-02-06 | NBIX | Abernethy Matt | CFO | S - Sale | $102.61 | -28,588 | 25,213 | -53% | -$2,933,470 | |||||
2023-01-31 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $109.99 | -1,457 | 26,171 | -5% | -$160,254 | ||||||
2023-01-31 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $108.48 | -126 | 2,477 | -5% | -$13,668 | ||||||
2023-01-31 | NBIX | Lloyd-Smith Malcolm | Chief Integration Officer | S - Sale | $110.02 | -1,666 | 28,582 | -6% | -$183,290 | ||||||
2023-01-31 | NBIX | Lippoldt Darin | GC | S - Sale | $109.97 | -1,250 | 30,357 | -4% | -$137,464 | ||||||
2023-01-31 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $110.08 | -2,707 | 465,278 | -1% | -$297,997 | ||||||
2023-01-31 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $109.99 | -1,541 | 112,820 | -1% | -$169,486 | ||||||
2023-01-31 | NBIX | Cooke Julie | CHRO | S - Sale | $108.48 | -916 | 15,926 | -5% | -$99,368 | ||||||
2023-01-31 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $109.92 | -1,104 | 3,911 | -22% | -$121,349 | ||||||
2023-01-31 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $109.95 | -1,207 | 16,729 | -7% | -$132,710 | ||||||
2023-01-31 | NBIX | Abernethy Matt | CFO | S - Sale | $109.98 | -1,283 | 21,357 | -6% | -$141,108 | ||||||
| D | 2023-01-06 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $125.00 | -400 | 15,643 | -2% | -$50,000 | |||||
| D | 2023-01-03 | NBIX | Sherwin Stephen A | Dir | S - Sale+OE | $118.86 | -30,000 | 25,055 | -54% | -$3,565,728 | |||||
| D | 2023-01-03 | NBIX | Pops Richard F | Dir | S - Sale+OE | $119.20 | -15,000 | 29,512 | -34% | -$1,788,045 | |||||
| D | 2022-11-30 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $125.90 | -50,000 | 15,643 | -76% | -$6,295,085 | |||||
2022-11-29 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $121.91 | -2,331 | 2,366 | -50% | -$284,160 | ||||||
| DM | 2022-11-08 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $125.33 | -24,693 | 15,643 | -61% | -$3,094,856 | |||||
| D | 2022-11-08 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $125.04 | -5,082 | 29,234 | -15% | -$635,442 | |||||
| D | 2022-11-08 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $124.99 | -5,592 | 15,102 | -27% | -$698,949 | |||||
| D | 2022-11-03 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $125.02 | -4,518 | 29,234 | -13% | -$564,851 | |||||
| DM | 2022-11-02 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $125.00 | -8,408 | 15,102 | -36% | -$1,050,997 | |||||
| DM | 2022-11-02 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $125.02 | -9,368 | 15,643 | -37% | -$1,171,183 | |||||
| D | 2022-10-31 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $114.76 | -15,000 | 203,697 | -7% | -$1,721,403 | |||||
| DM | 2022-11-01 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $120.28 | -10,400 | 29,234 | -26% | -$1,250,899 | |||||
2022-10-31 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $114.12 | -1,295 | 2,919 | -31% | -$147,785 | ||||||
| DM | 2022-10-26 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $115.03 | -10,000 | 29,234 | -25% | -$1,150,297 | |||||
2022-10-17 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $110.82 | -4,960 | 15,643 | -24% | -$549,682 | ||||||
2022-10-03 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $106.59 | -1,437 | 4,214 | -25% | -$153,170 | ||||||
2022-10-04 | NBIX | Lyons Gary A | Dir | S - Sale | $110.54 | -5,000 | 203,697 | -2% | -$552,711 | ||||||
| D | 2022-10-04 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $111.05 | -10,000 | 29,234 | -25% | -$1,110,446 | |||||
| D | 2022-08-12 | NBIX | Lloyd-Smith Malcolm | Chief Regulatory Officer | S - Sale+OE | $105.95 | -21,533 | 26,931 | -44% | -$2,281,331 | |||||
2022-06-27 | NBIX | Cooke Julie | CHRO | S - Sale | $100.00 | -754 | 16,918 | -4% | -$75,400 | ||||||
| D | 2022-05-09 | NBIX | Pops Richard F | Dir | S - Sale+OE | $76.30 | -15,000 | 29,512 | -34% | -$1,144,463 | |||||
| D | 2022-04-25 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $92.76 | -15,000 | 208,697 | -7% | -$1,391,393 | |||||
| D | 2022-04-01 | NBIX | Rastetter William H | Dir | S - Sale+OE | $94.93 | -10,728 | 34,022 | -24% | -$1,018,366 | |||||
| M | 2022-03-18 | NBIX | Lippoldt Darin | GC | S - Sale | $95.05 | -8,755 | 29,396 | -23% | -$832,156 | |||||
| M | 2022-02-07 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $79.99 | -940 | 2,919 | -24% | -$75,193 | |||||
| M | 2022-02-07 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $80.45 | -3,724 | 24,625 | -13% | -$299,590 | |||||
| M | 2022-02-07 | NBIX | Lloyd-Smith Malcolm | Chief Regulatory Officer | S - Sale | $80.48 | -3,382 | 18,731 | -15% | -$272,168 | |||||
| M | 2022-02-07 | NBIX | Lippoldt Darin | GC | S - Sale | $80.45 | -4,079 | 38,112 | -10% | -$328,160 | |||||
| M | 2022-02-07 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $80.54 | -10,984 | 462,844 | -2% | -$884,674 | |||||
| M | 2022-02-07 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $80.61 | -6,880 | 111,173 | -6% | -$554,628 | |||||
| M | 2022-02-07 | NBIX | Cooke Julie | CHRO | S - Sale | $80.38 | -2,858 | 17,411 | -14% | -$229,727 | |||||
| M | 2022-02-07 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $80.57 | -5,099 | 20,338 | -20% | -$410,821 | |||||
| M | 2022-02-07 | NBIX | Abernethy Matt | CFO | S - Sale | $80.53 | -4,290 | 20,204 | -18% | -$345,486 | |||||
| D | 2022-01-24 | NBIX | Sherwin Stephen A | Dir | S - Sale+OE | $74.43 | -15,000 | 25,055 | -37% | -$1,116,378 | |||||
2022-01-10 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $74.50 | -2,632 | 21,279 | -11% | -$196,088 | ||||||
| D | 2022-01-05 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale+OE | $85.50 | -28,266 | 104,984 | -21% | -$2,416,751 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |